Table 3 Outcomes in the unmatched and propensity score matched cohorts
From: Mid-term outcomes of Sapien 3 versus Perimount Magna Ease for treatment of severe aortic stenosis
Unmatched cohort | Propensity score matched cohort | |||||
|---|---|---|---|---|---|---|
Outcomes | Sapien 3 (N = 689) | Perimount Magna Ease (N = 1311) | p-value | Sapien 3 (N = 308) | Perimount Magna Ease (N = 308) | p-value |
In-hospital death | 8 (1.2) | 26 (2.0) | 0.177 | 4 (1.3) | 11 (3.6) | 0.092 |
Stroke | 9 (1.3) | 48 (3.7) | 0.003 | 1 (0.3) | 11 (3.6) | 0.006 |
Vascular complications | < 0.0001 | < 0.0001 | ||||
Minor | 18 (2.6) | 0 | 8 (2.6) | 0 | ||
Major | 58 (8.4) | 13 (1.0) | 29 (9.4) | 2 (0.6) | ||
Annulus rupture | 2 (0.3) | 0 | 1 (0.3) | 0 | ||
Aortic dissection/rupture | 2 (0.3) | 7 (0.5) | 0.727 | 1 (0.3) | 1 (0.3) | 1.000 |
Coronary ostium occlusion | 2 (0.3) | 2 (0.2) | 0.612 | 1 (0.3) | 2 (0.6) | 1.000 |
Acute kidney injury stages 2–3 | 5 (0.7) | 72 (5.5) | < 0.0001 | 1 (0.3) | 24 (7.8) | < 0.0001 |
Postoperative dialysis | 2 (0.3) | 20 (1.5) | 0.012 | 0 | 7 (2.3) | 0.015 |
Moderate/severe paravalvular regurgitation | 8 (1.2) | 10 (0.8) | 0.370 | 6 (1.9) | 4 (1.3) | 0.754 |
Severe bleeding* | 14 (2.1) | 282 (21.9) | < 0.0001 | 4 (1.3) | 88 (29.0) | < 0.0001 |
Reoperation for bleeding | 14 (2.0) | 129 (9.8) | < 0.0001 | 7 (2.3) | 33 (10.7) | < 0.0001 |
Red blood cell transfusion, units | 0.3 (1.1) | 2.6 (3.4) | < 0.0001 | 0.27 (1.0) | 3.2 (3.5) | < 0.0001 |
Postoperative IABP or ECMO | 0 | 11 (0.8) | 0.020 | 0 | 3 (1.0) | 0.249 |
Atrial fibrillation | 269 (39.0) | 733 (55.9) | < 0.0001 | 102 (33.1) | 200 (64.9) | < 0.0001 |
Permanent pacemaker implantation | 52 (7.5) | 47 (3.6) | < 0.0001 | 28 (9.1) | 16 (5.2) | 0.064 |
Hospital stay, days | 4.0 ± 3.4 | 7.7 ± 5.5 | < 0.0001 | 4.1 ± 3.7 | 8.4 ± 6.8 | < 0.0001 |